All Articles by Author:

lbeveridge

Ubiquitin-Binding Domain in ABIN1 Is Critical for Regulating Cell Death and Inflammation during Development

[Cell Death & Differentiation] Researchers demonstrated the importance of the ABIN1 UBD domain, which mediated the ABIN1-A20 axis, at limiting RIPK1 activation-dependent cell death during embryonic development.

A Common Framework of Monocyte-Derived Macrophage Activation

[Science Immunology] The authors contextualized macrophage heterogeneity across mouse tissues and inflammatory conditions, specifically aiming to define a common framework of macrophage activation.

Androgen Conspires with the CD8+ T Cell Exhaustion Program and Contributes to Sex Bias in Cancer

[Science Immunology] Investigators established a role for CD8+ T cell-dependent anti-tumor immunity in mediating sex differences in tumor aggressiveness, which was driven by the gonadal androgen but not sex chromosomes.

Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1

[Cancer Discovery] In mouse models, vitamin E (VitE) increased immune checkpoint therapy antitumor efficacy, which depended on dendritic cells (DCs). VitE entered DCs via SCARB1 receptor and restored tumor-associated DCs' functionality by directly binding to and inhibiting protein tyrosine phosphatase SHP1, a DC-intrinsic checkpoint.

Interaction between Macrophages and Ferroptosis

[Cell Death & Disease] Investigators discuss the interaction between macrophages and ferroptosis concerning three metabolisms and integrate the application of certain relationship in curing diseases, mostly cancer.

The Gut Microbial Metabolite Formate Exacerbates Colorectal Cancer Progression

[Nature Metabolism] Researchers showed that formate, a metabolite produced by the colorectal cancer (CRC)-associated bacterium Fusobacterium nucleatum, promoted CRC development, and that microbiome-derived formate drove CRC tumor invasion by triggering AhR signaling, while increasing cancer stemness.

Popular

Merck Announces Phase III KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal...

[Merck & Co., Inc.] Merck announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA®, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival for the first-line treatment of patients with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Androgen Receptor Splice Variants Drive Castration-Resistant Prostate Cancer Metastasis by Activating Distinct Transcriptional Programs

[Journal Of Clinical Investigation] Investigators found that, under castrated conditions, androgen receptor (AR)-V7 strongly induced osteoblastic bone lesions, a response not observed with full-length AR overexpression.

Prostate Cancer Screening Methods Trialed in ‘Pivotal Moment’

[The Guardian] Methods of screening men for prostate cancer will be trialed in an attempt to save thousands of lives in the UK each year, in what has been hailed as a “pivotal moment” by experts.